Michael E. Luggen, MD

Chalhoub, N E; Luggen, M E 2019. Screening for cognitive dysfunction in systemic lupus erythematosus: the Montreal Cognitive Assessment Questionnaire and the Informant Questionnaire on Cognitive Decline in the Elderly. Lupus, 28 1, 51-58

Gulati, Gaurav; Iffland, Philip H; Janigro, Damir; Zhang, Bin; Luggen, Michael E 2016. Anti-NR2 antibodies, blood-brain barrier, and cognitive dysfunction. Clinical rheumatology, 35 12, 2989-2997

Luggen, Michael E; Gulati, Gaurav; Zhang, Bin; Willis, Rohan A; Gonzalez, Emilio B 2016. Non-criteria anti-phospholipid antibodies and cognitive impairment in SLE. Clinical rheumatology, 35 1, 93-9

Antonchak, Marc A; Saoudian, Mahnaz; Khan, Amber R; Brunner, Hermine I; Luggen, Michael E 2011. Cognitive dysfunction in patients with systemic lupus erythematosus: a controlled study. The Journal of rheumatology, 38 6, 1020-5

Wasko, Mary Chester M; Hubert, Helen B; Lingala, Vijaya Bharathi; Elliott, Jennifer R; Luggen, Michael E; Fries, James F; Ward, Michael M 2007. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA, 298 2, 187-93

Kremer, Joel M; Genovese, Mark C; Cannon, Grant W; Caldwell, Jacques R; Cush, John J; Furst, Daniel E; Luggen, Michael E; Keystone, Ed; Weisman, Michael H; Bensen, William M; Kaine, Jeffrey L; Ruderman, Eric M; Coleman, Patricia; Curtis, David L; Kopp, Elliot J; Kantor, Seth M; Waltuck, Jonathan; Lindsley, Herbert B; Markenson, Joseph A; Strand, Vibeke; Crawford, Bruce; Fernando, Indra; Simpson, Karen; Bathon, Joan M 2002. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Annals of internal medicine, 137 9, 726-33

Mould, D R; Davis, C B; Minthorn, E A; Kwok, D C; Elliott, M J; Luggen, M E; Totoritis, M C 1999. A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis. Clinical pharmacology and therapeutics, 66 3, 246-57

Williams, H J; Alarcon, G S; Joks, R; Steen, V D; Bulpitt, K; Clegg, D O; Ziminski, C M; Luggen, M E; St Clair, E W; Willkens, R F; Yarboro, C; Morgan, J G; Egger, M J; Ward, J R 1999. Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. The Journal of rheumatology, 26 4, 816-25

Williams, H J; Alarcón, G S; Neuner, R; Steen, V D; Bulpitt, K; Clegg, D O; Ziminski, C M; Luggen, M E; Polisson, R P; Willkens, R F; Yarboro, C; Morgan, J; Egger, M J; Ward, J R 1998. Early undifferentiated connective tissue disease. V. An inception cohort 5 years later: disease remissions and changes in diagnoses in well established and undifferentiated connective tissue diseases. The Journal of rheumatology, 25 2, 261-8

Alarcón, G S; Willkens, R F; Ward, J R; Clegg, D O; Morgan, J G; Ma, K N; Singer, J Z; Steen, V D; Paulus, H E; Luggen, M E; Polisson, R P; Ziminski, C M; Yarboro, C; Williams, H J 1996. Early undifferentiated connective tissue disease. IV.Musculoskeletal manifestations in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of patients with well-established connective tissue diseases: followup analyses in patients with unexplained polyarthritis and patients with rheumatoid arthritis at baseline. Arthritis and rheumatism, 39 3, 403-14

Clegg, D O; Reda, D J; Mejias, E; Cannon, G W; Weisman, M H; Taylor, T; Budiman-Mak, E; Blackburn, W D; Vasey, F B; Mahowald, M L; Cush, J J; Schumacher, H R; Silverman, S L; Alepa, F P; Luggen, M E; Cohen, M R; Makkena, R; Haakenson, C M; Ward, R H; Manaster, B J; Anderson, R J; Ward, J R; Henderson, W G 1996. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis and rheumatism, 39 12, 2013-20

Clegg, D O; Reda, D J; Weisman, M H; Blackburn, W D; Cush, J J; Cannon, G W; Mahowald, M L; Schumacher, H R; Taylor, T; Budiman-Mak, E; Cohen, M R; Vasey, F B; Luggen, M E; Mejias, E; Silverman, S L; Makkena, R; Alepa, F P; Buxbaum, J; Haakenson, C M; Ward, R H; Manaster, B J; Anderson, R J; Ward, J R; Henderson, W G 1996. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis and rheumatism, 39 12, 2004-12

Luggen, M E 1994. [Duration of use of non-steroidal anti-inflammatory agents in patients with rheumatoid arthritis]. Revue du rhumatisme (Ed. francaise : 1993), 61 10 Pt 2, 165S-172S

Bulpitt, K J; Clements, P J; Lachenbruch, P A; Paulus, H E; Peter, J B; Agopian, M S; Singer, J Z; Steen, V D; Clegg, D O; Ziminski, C M; Alarcon, G S; Luggen, M E; Polisson, R P; Willkens, R F; Reading, J C; Williams, H J; Ward, J R 1993. Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Annals of internal medicine, 118 8, 602-9

Alarcón, G S; Williams, G V; Singer, J Z; Steen, V D; Clegg, D O; Paulus, H E; Billingsley, L M; Luggen, M E; Polisson, R P; Willkens, R F 1991. Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease. The Journal of rheumatology, 18 9, 1332-9

Clegg, D O; Williams, H J; Singer, J Z; Steen, V D; Schlegel, S; Ziminski, C; Alarcón, G S; Luggen, M E; Polisson, R P; Willkens, R F 1991. Early undifferentiated connective tissue disease. II. The frequency of circulating antinuclear antibodies in patients with early rheumatic diseases. The Journal of rheumatology, 18 9, 1340-3

Bendon, R W; Hayden, L E; Hurtubise, P E; Getahun, B; Siddiqi, T A; Glueck, H I; Luggen, M E; Gartside, P S 1990. Prenatal screening for anticardiolipin antibody. American journal of perinatology, 7 3, 245-50

Fritz, D A; Luggen, M E; Hess, E V 1989. Unusual longevity in primary systemic amyloidosis: a 19-year survivor. The American journal of medicine, 86 2, 245-8

Hess, E V; Luggen, M E 1989. Remodeling the pyramid--a concept whose time has not yet come. The Journal of rheumatology, 16 9, 1175-6

Luggen, M E; Gartside, P S; Hess, E V 1989. Nonsteroidal antiinflammatory drugs in rheumatoid arthritis: duration of use as a measure of relative value. The Journal of rheumatology, 16 12, 1565-9

Williams, H J; Ward, J R; Dahl, S L; Clegg, D O; Willkens, R F; Oglesby, T; Weisman, M H; Schlegel, S; Michaels, R M; Luggen, M E 1988. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis and rheumatism, 31 6, 702-13

Alarcón, G S; Billingsley, L M; Clegg, D O; Hardin, J G; Klippel, J; Luggen, M E; Polisson, R P; Singer, J Z; Szydlo, L; Willkens, R F 1987. Lack of association between HLA-DR2 and clinical response to methotrexate in patients with rheumatoid arthritis. Arthritis and rheumatism, 30 2, 218-20

Thun, M; Tanaka, S; Smith, A B; Halperin, W E; Lee, S T; Luggen, M E; Hess, E V 1987. Morbidity from repetitive knee trauma in carpet and floor layers. British journal of industrial medicine, 44 9, 611-20

Tanaka, S; Halperin, W E; Smith, A B; Lee, S T; Luggen, M E; Hess, E V 1985. Skin effects of occupational kneeling. American journal of industrial medicine, 8 4-5, 341-9

Williams, H J; Willkens, R F; Samuelson, C O; Alarcón, G S; Guttadauria, M; Yarboro, C; Polisson, R P; Weiner, S R; Luggen, M E; Billingsley, L M 1985. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and rheumatism, 28 7, 721-30

Stewart, J; Luggen, M E; Valtin, H 1972. A computer model of the renal countercurrent system. Kidney international, 2 5, 253-63

Kocharla L.;Taylor J.;Weiler T.;Ting T.;Luggen M.;Brunner H. 12-01-2009. Monitoring methotrexate toxicity in juvenile idiopathic arthritis Journal of Rheumatology, 36 12, 2813-2818

Wasko M.;Hubert H.;Lingala V.;Elliott J.;Luggen M.;Fries J.;Ward M. 11-28-2007. Risk of diabetes in patients with rheumatoid arthritis taking hydroxychloroquine: Reply [5] Journal of the American Medical Association, 298 20, 2369-2370

Ahmed M.;Luggen M.;Herman J.;Weiss K.;Decourten-Myers G.;Quinlan J.;Khanna D. 11-01-2006. Hypertrophic pachymeningitis in rheumatoid arthritis after adalimumab administration Journal of Rheumatology, 33 11, 2344-2346

Adhikari T.;Piatti A.;Luggen M. 10-01-2011. Cognitive dysfunction in SLE: Development of a screening tool Lupus, 20 11, 1142-1146

Genovese M.C.;Becker J.C.;Schiff M.;Luggen M.;Sherrer Y.;Kremer J.;Birbara C.;Box J.;Natarajan K.;Nuamah I.;Li T.;Aranda R.;Hagerty D.T.;Dougados M. 09-15-2005. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor ? inhibition New England Journal of Medicine, 353 11, 1114-1123

Genovese M.C.;Schiff M.;Luggen M.;Le Bars M.;Aranda R.;Elegbe A.;Dougados M. 08-01-2012. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid a Journal of Rheumatology, 39 8, 1546-1554

Kremer J.;Genovese M.;Cannon G.W.;Caldwell J.;Cush J.;Furst D.E.;Luggen M.;Keystone E.;Bathon J.;Kavanaugh A.;Ruderman E.;Coleman P.;Curtis D.;Kopp E.;Kantor S.;Weisman M.;Waltuck J.;Lindsley H.B.;Markenson J.;Crawford B.;Fernando I.;Simpson K.;Strand V. 08-01-2004. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis Journal of Rheumatology, 31 8, 1521-1531

Moreland L.W.;Alten R.;Van Den Bosch F.;Appelboom T.;Leon M.;Emery P.;Cohen S.;Luggen M.;Shergy W.;Nuamah I.;Becker J.C. 06-22-2002. Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, p Arthritis and Rheumatism, 46 6, 1470-1479

Keystone E.;Kremer J.;Russell A.;Box J.;Abud-Mendoza C.;Elizondo M.;Luo A.;Aranda R.;Delaet I.;Swanink R.;Gujrathi S.;Luggen M. 06-01-2012. Abatacept in subjects who switch from intravenous to subcutaneous therapy: Results from the phase II Annals of the Rheumatic Diseases, 71 6, 857-861

Vincenti F.;Luggen M. 05-11-2007. T cell costimulation: A rational target in the therapeutic armamentarium for autoimmune diseases and Annual Review of Medicine, 58 , 347-358

Genovese M.C.;Schiff M.;Luggen M.;Becker J.C.;Aranda R.;Teng J.;Li T.;Schmidely N.;Le Bars M.;Dougados M. 04-01-2008. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatme Annals of the Rheumatic Diseases, 67 4, 547-554

Tugwell P.;Bombardier C.;Buchanan W.W.;Goldsmith C.;Grace E.;Bennett K.J.;Williams H.J.;Egger M.;Alarcon G.S.;Guttadauria M.;Yarboro C.;Polisson R.P.;Szydlo L.;Luggen M.E.;Billingsley L.M.;Ward J.R.;Marks C. 03-20-1990. Methotrexate in rheumatoid arthritis. Impact on quality of life assessed by traditional standard-ite Archives of Internal Medicine, 150 1, 59-62

Weinblatt M.;Schiff M.;Goldman A.;Kremer J.;Luggen M.;Li T.;Chen D.;Becker J. 02-01-2007. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis whil Annals of the Rheumatic Diseases, 66 2, 228-234

Luggen M. 02-01-2004. Trials Are Short, Disease Long: Measuring Drug Utility Beyond Clinical Trials Journal of Rheumatology, 31 2, 205-206

Farhey Y.;Luggen M. 01-01-1998. Seropositive, symmetric polyarthritis in a patient with poorly differentiated lung carcinoma: Carcin Arthritis and Rheumatism, 11 2, 146-149

Luggen M.;Belhorn L.;Evans T.;Fitzgerald O.;Spencer-Green G. 01-01-1995. The evolution of Raynaud's phenomenon: A longterm prospective study Journal of Rheumatology, 22 12, 2226-2232

Luggen M.;Hess E.;Gartside P. 01-01-1990. Measure of relative value of drugs in RA (I: Reply) Journal of Rheumatology, 17 7, 979

Williams H.J.;Furst D.E.;Dahl S.L.;Steen V.D.;Marks C.;Alpert E.J.;Henderson A.M.;Samuelson C.O.;Dreyfus J.N.;Weinstein A.;Maclaughlin E.J.;Alarcón G.S.;Kaplan S.B.;Guttadauria M.;Luggen M.E.;Reading J.C.;Egger M.J.;Ward J.R. 01-01-1985. Double?blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline fo Arthritis & Rheumatism, 28 3, 308-314